ReviewJournal of blood medicine2016
Update and new approaches in the treatment of Castleman disease.
Review in Journal of blood medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 118 citations in OpenAlex.
- Article
- Oligocentric Castleman Disease (OligoCD): A Novel Diagnostic Entity in the Spectrum of Castleman Disease.Cureus · 2025Article
- A case report of Castleman disease with paraneoplastic pemphigus and bronchiolitis obliterans: Challenges and key takeaways.International journal of surgery case reports · 2025Article
- Unicentric Castleman disease with paraneoplastic pemphigus in a young woman: a case report.Frontiers in medicine · 2025Article
- Mediastinal Castleman disease presenting as a paraspinal mass causing back pain and shortness of breath in a young adult.Heliyon · 2024Article
- Reply to: Differential diagnosis between Kaposi sarcoma-associated herpesvirus cytokine syndrome and hemophagocytic lymphohistiocytosis.Infection · 2024Article
- Hyaline Vascular Variant of Castleman Disease of the Tonsil in an Adolescent: A case Report.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- A rare case report of hyaline-vascular type Castleman disease in the presacral region.Frontiers in oncology · 2024Article
- Systemic lupus erythematosus combined with Castleman disease and secondary paraneoplastic pemphigus: a case report.Pediatric rheumatology online journal · 2023Article
- Article
- Hyaline-vascular type unicentric Castleman disease with dysplastic follicular dendritic cell proliferative lesions: a case report.Journal of surgical case reports · 2023Article
- Transformation of HHV-8-negative idiopathic multicentric Castleman disease into diffuse large B-cell lymphoma: A case report from Nepal.Clinical case reports · 2023Article
- Analysis of characteristics of four patients with adrenal unicentric Castleman disease.Frontiers in endocrinology · 2023Article
- Misdiagnosis of renal pelvic unicentric Castleman disease: a case report.Frontiers in surgery · 2023Article
- Article
- Induction immunotherapy followed by surgery for hilar unicentric Castleman disease.Thoracic cancer · 2022Article
- Castleman Disease: A Multicenter Case Series from TurkeyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2022Article
- Cytokine Storm in COVID-19: Immunopathogenesis and Therapy.Medicina (Kaunas, Lithuania) · 2022Review
- Long-term treatment outcome of Castleman's disease: A real-world experience.Frontiers in oncology · 2022Article
- Iron-Refractory Iron Deficiency Anemia in an 11-year-old Girl.Pediatrics in review · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First described 60 years ago, Castleman disease comprises a rare and heterogeneous cluster of disorders, characterized by lymphadenopathy with unique histological features and associated with cytokine-driven constitutional symptoms and biochemical disturbances. Although unicentric Castleman disease is curable with complete surgical excision, its multicentric counterpart is a considerable therapeutic challenge. The recent development of biological agents, particularly monoclonal antibodies to interleukin-6 and its receptor, allow for more targeted disease-specific intervention that promises improved response rates and more durable disease control; however, further work is required to fill knowledge gaps in terms of underlying pathophysiology and to facilitate alternative treatment options for refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.